OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Hantel on Environmental and Health Impacts of Decentralizing Cancer Care

August 15th 2024

Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.

Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC

August 15th 2024

Soki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.

Dr Raez on the FDA Approval of Repotrectinib in NTRK+ Solid Tumors

August 14th 2024

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular Carcinoma

August 14th 2024

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

Dr Long on Unmet Needs in BRAF-Mutant Melanoma

August 14th 2024

Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.

Dr Feldman on the Prevention and Management of Breast Cancer–Related Lymphedema

August 14th 2024

Sheldon Feldman, MD, discusses prevention and management strategies for breast cancer–related lymphedema.

Dr Serzan on the Rationale for Evaluating Botensilimab Plus Balstilimab in Advanced RCC

August 14th 2024

Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.

Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer

August 14th 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.

Dr Bertossi on the Role of Centralized Academic Reference Diagnostics and Biobanking in Clinical Trials

August 14th 2024

Consuelo Bertossi, MD, discusses centralized academic reference diagnostics and biobanking in prospective, multicenter clinical trials.

Dr Thompson on the Necessity of Surgery and Radiation Therapy in Early-Stage Breast Cancer

August 14th 2024

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing challenges in determining the optimal treatment strategy for patients with early-stage breast cancer.

Dr Yee on Neoadjuvant Datopotamab Deruxtecan in High-Risk, Early-Stage Breast Cancer

August 13th 2024

Douglas Yee, MD, discusses neoadjuvant datopotamab deruxtecan in early-stage breast cancer

Dr Llombart-Cussac on the Implications of Prophylaxis for Neutropenia and Diarrhea in Advanced Breast Cancer

August 13th 2024

Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Dr Li on the Rationale for a Post Hoc Analysis of KEYNOTE-057 in BCG-Unresponsive NMIBC

August 13th 2024

Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.

Dr Tedeschi on Long-Term Data With First-Line Ibrutinib in CLL

August 13th 2024

Alessandra Tedeschi, MD, discusses 10-year follow-up data on treatment with first-line ibrutinib in treatment-naive chronic lymphocytic leukemia.

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer

August 13th 2024

Adrienne G. Waks, MD, discusses how neoadjuvant and adjuvant anthracycline- and taxane-based regimens compare with one another in HER2+ breast cancer.

Dr Shouse on Currently Available Targeted Therapies for FL

August 13th 2024

Geoffrey Shouse, DO, PhD, discusses currently available targeted therapies for the management of follicular lymphoma.

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC

August 12th 2024

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Dr Garcia-Manero on the Investigation of Luspatercept Dose Levels in Low-Risk MDS

August 12th 2024

Guillermo Garcia-Manero, MD, discusses the investigation of luspatercept dose levels in patients with low-risk myelodysplastic syndrome who require red blood cell transfusions.

Dr Goodman on the Addition of CRT to Adjuvant Chemo in Pancreatic Head Adenocarcinomas

August 12th 2024

Karyn A. Goodman, MD, MS, discusses the use of chemoradiation after adjuvant chemotherapy in resected adenocarcinomas of the pancreatic head.

Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple Myeloma

August 12th 2024

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.